This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted
in the United States in subjects with atopic dermatitis.

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)

Atopic Dermatitis

Tradipitant

Placebo

A Randomized, Double-Blind, Placebo-Controlled Efficacy Study of The Neurokinin-1 Receptor Antagonist VLY-686 in Patients With Atopic Dermatitis

Reduction of worst itch in atopic dermatitis as measured by Numerical Rating Scale (NRS).
Worst Itch NRS is an assessment tool that is used to report the maximum intensity of
participant's itch during a 24-hour recall period. Participants were asked the following
question: Please rate the itching severity that describes your worst level of itching in
the past 24 hours [0=No Itch, 10=Worst Itch Imaginable].

Proportion of participants achieving 50% reduction on the SCORing Atopic Dermatitis
(SCORAD) index. SCORAD is an assessment scale used to determine the severity of AD.
SCORAD combines the investigator's rating of extent and intensity and the patient
reported itch and sleep disturbance. Total score ranges from 0 (absent disease) to 103
(severe disease).

As measured by the validated Investigator Global Assessment for Atopic Dermatitis
(vIGA-AD). IGA is an assessment scale used to determine severity of AD. It is assessed by
the investigator on a 5-point scale (0=clear, 1=almost clear, 2=mild, 3=moderate,
4=severe) based on erythema, induration/papulation, lichenification, and oozing/crusting.

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)

About this trial

Study ID

Status

Type

Phase

Placebo

Accepting

Not accepting

Trial Timing

What is this trial about?

What are the participation requirements?